@article{076667404a39477ebe58c8efe98d1804,
title = "Mitochondrial defect in Warsaw syndrome cells genomic integrity and mitochondrial metabolism defects in Warsaw syndrome cells: A comparison with Fanconi anemia",
abstract = "Warsaw breakage syndrome (WABS), is caused by biallelic mutations of DDX11, a gene coding a DNA helicase. We have recently reported two affected sisters, compound heterozygous for a missense (p.Leu836Pro) and a frameshift (p.Lys303Glufs*22) variant. By investigating the pathogenic mechanism, we demonstrate the inability of the DDX11 p.Leu836Pro mutant to unwind forked DNA substrates, while retaining DNA binding activity. We observed the accumulation of patient-derived cells at the G2/M phase and increased chromosomal fragmentation after mitomycin C treatment. The phenotype partially overlaps with features of the Fanconi anemia cells, which shows not only genomic instability but also defective mitochondria. This prompted us to examine mitochondrial functionality in WABS cells and revealed an altered aerobic metabolism. This opens the door to the further elucidation of the molecular and cellular basis of an impaired mitochondrial phenotype and sheds light on this fundamental process in cell physiology and the pathogenesis of these diseases.",
keywords = "Fanconi anemia, genomic integrity, mitochondrial defects, oxidative stress, OXOPHOS, Warsaw syndrome",
author = "Roberta Bottega and Silvia Ravera and Napolitano, {Luisa M.R.} and Viviana Chiappetta and Nicoletta Zini and Barbara Crescenzi and Silvia Arniani and Michela Faleschini and Giuseppe Cortone and Flavio Faletra and Barbara Medagli and Fabio Sirchia and Martina Moretti and {de Lange}, Job and Enrico Cappelli and Cristina Mecucci and Silvia Onesti and Pisani, {Francesca M.} and Anna Savoia",
note = "Funding Information: This study was supported by IRCCS “Burlo Garofolo” (Ricerca Corrente 03/2018); AIRC Grants IG‐14718, IG‐20778, and IG‐21974; the European Union's Horizon 2020 research and innovation program grant Agreement N° 859853 (MSCA‐ETN 2019, “AntiHelix”); Consorzio CNCCS (“Progetto B—Ricerca di nuovi farmaci per malattie rare trascurate e della povert{\`a}”); Regione Campania (POR‐FESR 2014‐2020, “Progetto SATIN”); AIRC 5xmille, MYNERVA Project; the Cross‐border Cooperation Programme Italy‐Slovenia 2014–2020 by the European Regional Development Fund and national funds (TransGlioma). We thank the Elettra Protein Production Facility for the technical support. The authors thank the patients for their participation in this project and Prof. D. L. Gughi and Prof. F. Dede for the constructive discussions. Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
doi = "10.1002/jcp.30265",
language = "English",
journal = "Journal of Cellular Physiology",
issn = "1097-4652",
publisher = "Wiley-Liss Inc.",
}